MIA
IBRX icon

MeadowBrook Investment Advisors’s ImmunityBio IBRX Stock Holding History

MeadowBrook Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$744 – 327
2024
Q3 		$744 Hold
200
– – ﹤0.01% 329
2024
Q2 		$1.26K Hold
200
– – ﹤0.01% 306
2024
Q1 		$1.07K Hold
200
– – ﹤0.01% 319
2023
Q4 		$1K Buy
+200
New +$628 ﹤0.01% 330

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MeadowBrook Investment Advisors's IBRX Position: Q4 2024 in Review

MeadowBrook Investment Advisors sold out of ImmunityBio (IBRX) in Q4 2024, closing a stake of 200 shares — an estimated $744 sold.

MeadowBrook Investment Advisors first reported a position in IBRX in Q4 2023 and held it in 4 quarters. The position peaked at $1.26K in Q2 2024. 201 funds tracked by Wall St. Rank hold IBRX as of Q4 2024.

  • MeadowBrook Investment Advisors reported no remaining ImmunityBio position as of Q4 2024 after selling out during the quarter.
  • MeadowBrook Investment Advisors sold 200 ImmunityBio shares in Q4 2024, an estimated $744.
  • MeadowBrook Investment Advisors first reported a position in ImmunityBio in Q4 2023 and held it in 4 quarters.
  • MeadowBrook Investment Advisors's ImmunityBio position peaked at $1.26K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2024.

Based on MeadowBrook Investment Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.